Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Appili Therapeutics Inc. has reported significant progress in the first quarter of FY 2025, including a definitive agreement with Aditxt that promises a substantial premium for shareholders, development advancements in their drug programs, and the successful launch of their FDA-approved drug LIKMEZ™ with Saptalis Pharmaceuticals. The company has secured funding from the U.S. Air Force Academy for their biodefense vaccine candidate ATI-1701 and is in discussions with the FDA for their antiparasitic product ATI-1801.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.